Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Clinical trial NCT03679598 · COMPLETED

Trial details

NCT number: NCT03679598
Sponsor: University of Alabama at Birmingham
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alpha-1 Antitrypsin Deficiency (AATD)Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations Emphysema or COPD

Start date: 2019-04-08
Primary completion: 2023-11-30
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.